Lilly, GSK and Janssen join UK government's $100 million Dementia Discovery Fund
The UK’s Health Secretary Jeremy Hunt has announced a collaborative dementia research initiative between the government, leading dementia charity Alzheimer’s Research UK and major pharma companies.
The $100 million Dementia Discovery Fund will invest in innovative preclinical research aimed at developing new drugs for dementia. UK pharma major GlaxoSmithKline (LSE: GSK) has made a $25 million investment, Eli Lilly (NYSE: LLY) is also a partner, and Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen has invested $10 million.
Janssen researchers are studying hallmarks of the illness, including amyloid plaques, tau tangles and loss of nerve cell connections in the brain, all of which can lead to Alzheimer's dementia. GSK has in-house research teams focused on neurodegenerative diseases including dementia at its dedicated neuroscience facility in Shanghai.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze